ITPR3 and prostate cancer: The upregulation of ITPR3 was observed in several malignancies, such as cholangiocarcinoma (Ueasilamongkol et al., 2020), colon cancer (Shibao et al., 2010), melanoma (Kuchay et al., 2017), colorectal cancer (Shibao et al., 2010), cervical squamous cell carcinoma cancer (Yang et al., 2017), glioblastoma (Kang et al., 2010), hepatocellular carcinoma (HCC) (Guerra et al., 2019), mesothelioma, and prostate cancer (Bononi et al., 2017).The upregulation of ITPR3 plays an essential role in T-lymphocyte apoptosis (Khan et al., 1996).